AI Science Tracker

Machine-learning-guided PBMC proteomics identifies SLE diagnosis and activity biomarker panels

Jinan University; Shenzhen People’s Hospital; collaborating institutions · 29 Nov 2022 · medicine

Discovery

Machine-learning-guided PBMC proteomics identifies SLE diagnosis and activity biomarker panels

A random-forest and OPLS-DA prioritization pipeline applied to peripheral-blood mononuclear-cell proteomics identified candidate protein combinations for distinguishing systemic lupus erythematosus (SLE) from healthy and rheumatoid-arthritis controls and for separating active from inactive SLE. ELISA in a separate 80-person cohort supported a six-protein diagnosis panel (IFIT3, MX1, TOMM40, STAT1, STAT2 and OAS3; AUC 0.723 versus healthy controls and 0.815 versus rheumatoid arthritis) and a nine-protein activity panel (AUC 0.990). Single-cell RNA-sequencing analysis mapped several associated interferon-signature proteins to specific immune-cell populations.

Technology: POC-SLE: random-forest feature ranking with 1,000 bootstrap iterations, combined with OPLS-DA variable-importance selection

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: ELISA in a separate 80-person cohort supported a six-protein diagnosis panel (IFIT3, MX1, TOMM40, STAT1, STAT2 and OAS3; AUC 0.723 versus healthy controls and 0.815 versus rheumatoid arthritis) and a nine-protein activity panel (AUC 0.990).
  • Still unknown: The study is cross-sectional and the ELISA validation cohort contained 80 people from the same clinical setting; it does not establish longitudinal flare prediction, treatment response, causal mechanisms or clinical utility. The six-protein panel had moderate discrimination versus healthy controls (AUC 0.723) and better but still cohort-specific discrimination versus rheumatoid arthritis (AUC 0.815). The activity-panel AUC of 0.990 was reported for active versus inactive groups in this validation cohort and needs broader independent validation. Authors note limited sample size/ethnic diversity and need for mechanistic study.
  • AI role: The random forest ranked differentially expressed proteins from discovery-cohort PBMC proteomics; its selected proteins were intersected with OPLS-DA features to construct candidate diagnosis and activity panels. Researchers evaluated those panels with ELISA in a separate cohort and used single-cell transcriptomic data to examine immune-cell sources.

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.969509/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 73 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.